Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caribou Biosciences filings document a clinical-stage CRISPR genome-editing biopharmaceutical company focused on allogeneic CAR-T therapies. Recent 8-K reports furnish quarterly and annual financial results, cash and operating-plan disclosures, business updates, and Regulation FD disclosures covering vispa-cel and CB-011 clinical and FDA-related developments.
Proxy materials describe annual meeting matters, board elections, auditor ratification, and proposed charter governance changes for the Delaware corporation. Other event filings record public-company status matters, including Nasdaq bid-price compliance notices and product-candidate regulatory designations.
Caribou Biosciences Chief Business Officer Ruhi Ahmad Khan reported a mix of equity grants and a small tax-related share sale. On February 24, 2026, Khan sold 6,938 shares of common stock at $1.96 per share in an open-market transaction, leaving 104,998 shares held directly. A footnote explains this was a sell-to-cover trade executed under a Rule 10b5-1 plan solely to satisfy tax withholding on vesting RSUs, not a discretionary sale.
On February 20, 2026, Khan received a grant of 45,000 restricted stock units that vest in four equal annual installments beginning on February 20, 2027, with shares delivered within 30 days after each vesting date. On the same date, Khan was granted options for 202,500 shares of common stock, vesting monthly over 48 months so that the option is fully vested by February 20, 2030, contingent on continued service.
Caribou Biosciences Chief Medical Officer Tina M. Albertson reported a mix of equity grants and a small tax-related sale. She received 55,000 shares of common stock as restricted stock units that vest annually over four years starting on February 20, 2027. She was also granted an option for 247,500 shares of common stock, vesting monthly so that it is fully vested by February 20, 2030.
Separately, 1,066 common shares were sold at $1.96 per share in a sell-to-cover transaction to satisfy tax withholding on previously vested RSUs under a pre-established Rule 10b5-1 trading plan. After these transactions, she directly holds 68,523 common shares.
Caribou Biosciences director Zheng Ran received an option grant for 45,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory equity award rather than a market purchase.
According to the vesting terms, one-twelfth of the option shares vest on each monthly anniversary of the February 20, 2026 grant date, so the award will be fully vested by February 20, 2027, as long as Zheng Ran continues providing services to Caribou Biosciences through each vesting date.
Caribou Biosciences, Inc. reported that director Nancy Whiting received a grant of options to purchase 45,000 shares of common stock. The options have an exercise price of $0.00 per share, representing a compensatory award rather than a cash purchase.
According to the terms, one-twelfth of the option grant vests on each monthly anniversary of the grant date and will be fully vested by February 20, 2027, as long as she continues providing service to the company through each vesting date.
Sacks Natalie reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported that director Natalie Sacks received an option grant to purchase 45,000 shares of common stock. The option was awarded at a price of $0.00 per share, reflecting a no-cost equity award rather than an open-market purchase.
According to the vesting terms, one-twelfth of the option shares will vest on each monthly anniversary of the grant date, so the award will be fully vested by February 20, 2027, assuming she continues providing service to the company through each vesting date.
Caribou Biosciences, Inc. director Dara Richardson-Heron reported receiving an option grant to purchase 45,000 shares of common stock. The option was awarded at an exercise price of $0.0000 per share, reflecting a typical compensatory equity award rather than an open-market transaction.
According to the vesting terms, one-twelfth of the shares subject to this option vest on each monthly anniversary of the February 20, 2026 grant date. The option will be fully vested by February 20, 2027, as long as Richardson-Heron continues to provide service to Caribou Biosciences through each monthly vesting date.
JOHNSON DAVID LEE reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported that director David Lee Johnson received a grant of 45,000 options to purchase common stock. The options were awarded for no cash consideration and are held directly by Johnson.
According to the vesting terms, one-twelfth of the option shares vest on each monthly anniversary of the February 20, 2026 grant date, so the award will be fully vested by February 20, 2027, as long as Johnson continues providing service to the company through each vesting date.
Caribou Biosciences, Inc. director Andrew Guggenhime received a grant of options to purchase 45,000 shares of the company’s common stock. The options were awarded at an exercise price of $0.00 per share as a form of equity compensation.
According to the vesting terms, one-twelfth of the option grant vests on each monthly anniversary of the grant date, so the entire 45,000-share option will be fully vested by February 20, 2027, as long as Guggenhime continues to provide services to the company through each vesting date.
Caribou Biosciences, Inc. reported that director Scott Braunstein received a grant of options to purchase 45,000 shares of common stock at an exercise price of $0.00 per share. One-twelfth of the options vest monthly and will be fully vested by February 20, 2027, assuming continued service.
Caribou Biosciences, Inc. Chief Financial Officer Sriram Ryali reported equity awards consisting of stock options and restricted stock units. He was granted an option to purchase 247,500 shares of common stock at an exercise price of $0.00 per share.
The option vests over time, with 1/48 of the shares vesting monthly so that it is fully vested by February 20, 2030, contingent on continued service. He also received 55,000 shares of common stock in the form of RSUs that vest in four equal annual installments beginning on February 20, 2027, also subject to continued service, and will be settled in stock within 30 days after each vesting date.